Brief: PharmAla Biotech To Supply University Of Sydney Clinical Trial With LaNeo MDMA
31/08/2022 14:09
Aug 31 (Reuters) - PharmAla Biotech Holdings Inc MDMA.CD :
* PHARMALA BIOTECH TO SUPPLY UNIVERSITY OF SYDNEY CLINICAL
TRIAL
WITH LANEO™ MDMA
* PHARMALA BIOTECH HOLDINGS INC - PHARMALA'S LANEO MDMA WILL
BE
DELIVERED TO UNIVERSITY OF SYDNEY IN 2 TRANCHES, WITH DELIVERIES
BEGINNING IN EARLY 2023
Source text for Eikon: ID:nCNW8zvMFa
Further company coverage: MDMA.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmala Biotech Holdings
See all newsBrief: Pharmala Biotech Holdings Rua Bioscience And Pharmala Biotech Partner To Supply Medicinal Mdma In New Zealand
Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
Brief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
Brief: Pharmala Executes Binding Letter Of Intent For Formation Of Special Purpose Vehicle To Develop Patented Novel Mdxx Molecule Apa-01
Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders